

**Registered Number 04113581**

**CADILA PHARMACEUTICALS (EUROPE) LIMITED**

**Abbreviated Accounts**

**31 March 2015**

## Abbreviated Balance Sheet as at 31 March 2015

	Notes	2015	2014
		£	£
<b>Called up share capital not paid</b>		-	-
<b>Fixed assets</b>			
Intangible assets		-	-
Tangible assets	2	2,593,813	-
Investments	3	4,840	4,840
		<u>2,598,653</u>	<u>4,840</u>
<b>Current assets</b>			
Stocks		-	-
Debtors		236,691	413,707
Cash at bank and in hand		321,791	861,520
		<u>558,482</u>	<u>1,275,227</u>
<b>Creditors: amounts falling due within one year</b>		<u>(304,164)</u>	<u>(74,708)</u>
<b>Net current assets (liabilities)</b>		<u>254,318</u>	<u>1,200,519</u>
<b>Total assets less current liabilities</b>		<u>2,852,971</u>	<u>1,205,359</u>
<b>Total net assets (liabilities)</b>		<u>2,852,971</u>	<u>1,205,359</u>
<b>Capital and reserves</b>			
Called up share capital	4	2,960,986	1,205,815
Profit and loss account		(108,015)	(456)
<b>Shareholders' funds</b>		<u>2,852,971</u>	<u>1,205,359</u>

- For the year ending 31 March 2015 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

Approved by the Board on 25 June 2015

And signed on their behalf by:

**Dr R I Modi, Director**

**Notes to the Abbreviated Accounts for the period ended 31 March 2015****1 Accounting Policies****Basis of measurement and preparation of accounts**

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities effective April 2008.

**Turnover policy**

Turnover represents the total invoice value, excluding value added tax, of sales made during the year and derives from the provision of goods falling within the company's ordinary activities.

**Tangible assets depreciation policy**

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Land and buildings - Straight Line over 50 years

Fixtures and fittings - Straight Line over 10 years

Office equipment - Straight Line over 3-5 years

Motor vehicles - Straight Line over 8 years

**Other accounting policies****Investments**

Fixed asset investments are stated at cost less provision for permanent diminution in value.

**Foreign currencies**

Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rates of exchange prevailing at the accounting date. Transactions in foreign currencies are recorded at the date of the transactions. All differences are taken to the Profit and Loss account.

**Group accounts**

The company is entitled to the exemption under Section 398 of the Companies Act 2006 from the obligation to prepare group accounts.

**Ultimate parent undertaking**

The company's ultimate parent at the balance sheet date was Cadila Pharmaceuticals Limited, incorporated in India and the immediate undertaking at the balance sheet date was Satellite Overseas Holdings Ltd (SOHL), incorporated in Isle of Man.

**2 Tangible fixed assets**

	£
<b>Cost</b>	
At 1 April 2014	-
Additions	2,663,182
Disposals	-
Revaluations	-

Transfers	-
At 31 March 2015	<u>2,663,182</u>
<b>Depreciation</b>	
At 1 April 2014	-
Charge for the year	69,369
On disposals	-
At 31 March 2015	<u>69,369</u>
<b>Net book values</b>	
At 31 March 2015	<u>2,593,813</u>
At 31 March 2014	<u>-</u>

### 3 Fixed assets Investments

Investment details 31/03/15 31/03/14

Subsidiary undertaking £4,840 £4,840

Holdings of 20% or more

The company holds 20% or more of the share capital of the following companies:

Company - Subsidiary undertaking - Cadila Pharmaceuticals (Sweden) AB Sweden Country of registration or incorporation - Sweden Nature of business - Commission agents Shares held class - Ordinary shares % - 100%

The aggregate amount of capital and reserves and the results of these undertakings for the last relevant financial year were as follows:

Cadila Pharmaceuticals (Sweden) AB Sweden Capital and reserves - £577,334 Profit for the year - £113,123

### 4 Called Up Share Capital

Allotted, called up and fully paid:

	2015	2014
	£	£
2,960,986 Ordinary shares of £1 each (1,205,815 shares for 2014)	2,960,986	1,205,815

During the year, the company received £1,755,171 being consideration for allotment of 1,755,171 Ordinary shares at a nominal value of £1 each.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.